CareDx, Inc (CDNA) Stock Competitors & Peer Comparison
See (CDNA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CDNA | $22.31 | +1.09% | 1.2B | -139.44 | -$0.16 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.77% |
| TMO | $473.95 | -1.69% | 176.2B | 26.09 | $18.17 | +0.37% |
| DHR | $178.08 | +1.12% | 126.1B | 34.53 | $5.16 | +0.77% |
| IDXX | $560.73 | +1.80% | 44.2B | 41.20 | $13.61 | N/A |
| A | $137.40 | +1.74% | 38.9B | 27.66 | $4.97 | +0.56% |
| IQV | $182.05 | +0.78% | 30.4B | 22.59 | $8.06 | N/A |
| NTRA | $211.85 | -0.41% | 30.3B | -130.77 | -$1.62 | N/A |
| ILMN | $170.93 | +5.16% | 25.9B | 31.02 | $5.51 | N/A |
| WAT | $379.77 | +2.11% | 24.8B | 48.26 | $7.87 | N/A |
Stock Comparison
CDNA vs DHR-PB Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, CDNA is priced at $22.31, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, CDNA's ROE is -0.03%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, CDNA is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check DHR-PB's competition here
CDNA vs TMO Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, TMO has a market cap of 176.2B. Regarding current trading prices, CDNA is priced at $22.31, while TMO trades at $473.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas TMO's P/E ratio is 26.09. In terms of profitability, CDNA's ROE is -0.03%, compared to TMO's ROE of +0.13%. Regarding short-term risk, CDNA is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check TMO's competition here
CDNA vs DHR Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, DHR has a market cap of 126.1B. Regarding current trading prices, CDNA is priced at $22.31, while DHR trades at $178.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas DHR's P/E ratio is 34.53. In terms of profitability, CDNA's ROE is -0.03%, compared to DHR's ROE of +0.07%. Regarding short-term risk, CDNA is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check DHR's competition here
CDNA vs IDXX Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, IDXX has a market cap of 44.2B. Regarding current trading prices, CDNA is priced at $22.31, while IDXX trades at $560.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas IDXX's P/E ratio is 41.20. In terms of profitability, CDNA's ROE is -0.03%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, CDNA is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check IDXX's competition here
CDNA vs A Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, A has a market cap of 38.9B. Regarding current trading prices, CDNA is priced at $22.31, while A trades at $137.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas A's P/E ratio is 27.66. In terms of profitability, CDNA's ROE is -0.03%, compared to A's ROE of +0.21%. Regarding short-term risk, CDNA is less volatile compared to A. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check A's competition here
CDNA vs IQV Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, IQV has a market cap of 30.4B. Regarding current trading prices, CDNA is priced at $22.31, while IQV trades at $182.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas IQV's P/E ratio is 22.59. In terms of profitability, CDNA's ROE is -0.03%, compared to IQV's ROE of +0.22%. Regarding short-term risk, CDNA is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check IQV's competition here
CDNA vs NTRA Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, NTRA has a market cap of 30.3B. Regarding current trading prices, CDNA is priced at $22.31, while NTRA trades at $211.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas NTRA's P/E ratio is -130.77. In terms of profitability, CDNA's ROE is -0.03%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, CDNA is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check NTRA's competition here
CDNA vs ILMN Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, ILMN has a market cap of 25.9B. Regarding current trading prices, CDNA is priced at $22.31, while ILMN trades at $170.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas ILMN's P/E ratio is 31.02. In terms of profitability, CDNA's ROE is -0.03%, compared to ILMN's ROE of +0.34%. Regarding short-term risk, CDNA is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check ILMN's competition here
CDNA vs WAT Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, WAT has a market cap of 24.8B. Regarding current trading prices, CDNA is priced at $22.31, while WAT trades at $379.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas WAT's P/E ratio is 48.26. In terms of profitability, CDNA's ROE is -0.03%, compared to WAT's ROE of +0.08%. Regarding short-term risk, CDNA is less volatile compared to WAT. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check WAT's competition here
CDNA vs MTD Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, MTD has a market cap of 23.6B. Regarding current trading prices, CDNA is priced at $22.31, while MTD trades at $1,169.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas MTD's P/E ratio is 27.45. In terms of profitability, CDNA's ROE is -0.03%, compared to MTD's ROE of -6.10%. Regarding short-term risk, CDNA is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check MTD's competition here
CDNA vs DGX Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, DGX has a market cap of 21.5B. Regarding current trading prices, CDNA is priced at $22.31, while DGX trades at $193.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas DGX's P/E ratio is 21.41. In terms of profitability, CDNA's ROE is -0.03%, compared to DGX's ROE of +0.14%. Regarding short-term risk, CDNA is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check DGX's competition here
CDNA vs LH Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, LH has a market cap of 21.2B. Regarding current trading prices, CDNA is priced at $22.31, while LH trades at $258.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas LH's P/E ratio is 22.91. In terms of profitability, CDNA's ROE is -0.03%, compared to LH's ROE of +0.11%. Regarding short-term risk, CDNA is more volatile compared to LH. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check LH's competition here
CDNA vs EXAS Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, CDNA is priced at $22.31, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas EXAS's P/E ratio is -95.37. In terms of profitability, CDNA's ROE is -0.03%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, CDNA is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check EXAS's competition here
CDNA vs GH Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, GH has a market cap of 16.8B. Regarding current trading prices, CDNA is priced at $22.31, while GH trades at $127.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas GH's P/E ratio is -37.36. In terms of profitability, CDNA's ROE is -0.03%, compared to GH's ROE of +1.84%. Regarding short-term risk, CDNA is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check GH's competition here
CDNA vs PKI Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, CDNA is priced at $22.31, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas PKI's P/E ratio is 41.45. In terms of profitability, CDNA's ROE is -0.03%, compared to PKI's ROE of +0.03%. Regarding short-term risk, CDNA is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check PKI's competition here
CDNA vs MEDP Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, MEDP has a market cap of 12.9B. Regarding current trading prices, CDNA is priced at $22.31, while MEDP trades at $450.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas MEDP's P/E ratio is 28.41. In terms of profitability, CDNA's ROE is -0.03%, compared to MEDP's ROE of +1.21%. Regarding short-term risk, CDNA is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check MEDP's competition here
CDNA vs RVTY Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, RVTY has a market cap of 11.3B. Regarding current trading prices, CDNA is priced at $22.31, while RVTY trades at $101.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas RVTY's P/E ratio is 48.60. In terms of profitability, CDNA's ROE is -0.03%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, CDNA is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check RVTY's competition here
CDNA vs ICLR Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, ICLR has a market cap of 11B. Regarding current trading prices, CDNA is priced at $22.31, while ICLR trades at $143.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas ICLR's P/E ratio is 49.62. In terms of profitability, CDNA's ROE is -0.03%, compared to ICLR's ROE of +0.02%. Regarding short-term risk, CDNA is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check ICLR's competition here
CDNA vs CRL Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, CRL has a market cap of 8.7B. Regarding current trading prices, CDNA is priced at $22.31, while CRL trades at $179.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas CRL's P/E ratio is -48.47. In terms of profitability, CDNA's ROE is -0.03%, compared to CRL's ROE of -0.06%. Regarding short-term risk, CDNA is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check CRL's competition here
CDNA vs QGEN Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, QGEN has a market cap of 7.5B. Regarding current trading prices, CDNA is priced at $22.31, while QGEN trades at $36.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas QGEN's P/E ratio is 18.62. In terms of profitability, CDNA's ROE is -0.03%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, CDNA is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check QGEN's competition here
CDNA vs BLLN Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, BLLN has a market cap of 4.5B. Regarding current trading prices, CDNA is priced at $22.31, while BLLN trades at $98.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas BLLN's P/E ratio is 182.15. In terms of profitability, CDNA's ROE is -0.03%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, CDNA is less volatile compared to BLLN. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check BLLN's competition here
CDNA vs TWST Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, TWST has a market cap of 4.5B. Regarding current trading prices, CDNA is priced at $22.31, while TWST trades at $72.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas TWST's P/E ratio is -54.75. In terms of profitability, CDNA's ROE is -0.03%, compared to TWST's ROE of -0.17%. Regarding short-term risk, CDNA is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check TWST's competition here
CDNA vs SYNH Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, CDNA is priced at $22.31, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas SYNH's P/E ratio is 61.40. In terms of profitability, CDNA's ROE is -0.03%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, CDNA is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check SYNH's competition here
CDNA vs SHC Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, SHC has a market cap of 4.4B. Regarding current trading prices, CDNA is priced at $22.31, while SHC trades at $15.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas SHC's P/E ratio is 37.24. In terms of profitability, CDNA's ROE is -0.03%, compared to SHC's ROE of +0.21%. Regarding short-term risk, CDNA is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check SHC's competition here
CDNA vs RDNT Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, RDNT has a market cap of 4.1B. Regarding current trading prices, CDNA is priced at $22.31, while RDNT trades at $51.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas RDNT's P/E ratio is -305.12. In terms of profitability, CDNA's ROE is -0.03%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, CDNA is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check RDNT's competition here
CDNA vs OLK Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, CDNA is priced at $22.31, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas OLK's P/E ratio is -96.59. In terms of profitability, CDNA's ROE is -0.03%, compared to OLK's ROE of -0.07%. Regarding short-term risk, CDNA is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check OLK's competition here
CDNA vs GRAL Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, GRAL has a market cap of 2.6B. Regarding current trading prices, CDNA is priced at $22.31, while GRAL trades at $61.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas GRAL's P/E ratio is -5.93. In terms of profitability, CDNA's ROE is -0.03%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, CDNA is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check GRAL's competition here
CDNA vs NEOG Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, NEOG has a market cap of 1.9B. Regarding current trading prices, CDNA is priced at $22.31, while NEOG trades at $8.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas NEOG's P/E ratio is -3.15. In terms of profitability, CDNA's ROE is -0.03%, compared to NEOG's ROE of -0.29%. Regarding short-term risk, CDNA is more volatile compared to NEOG. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check NEOG's competition here
CDNA vs PSNL Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, PSNL has a market cap of 957.3M. Regarding current trading prices, CDNA is priced at $22.31, while PSNL trades at $10.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas PSNL's P/E ratio is -10.57. In terms of profitability, CDNA's ROE is -0.03%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, CDNA is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check PSNL's competition here
CDNA vs CSTL Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, CSTL has a market cap of 618.4M. Regarding current trading prices, CDNA is priced at $22.31, while CSTL trades at $20.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas CSTL's P/E ratio is -48.55. In terms of profitability, CDNA's ROE is -0.03%, compared to CSTL's ROE of -0.03%. Regarding short-term risk, CDNA is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check CSTL's competition here
CDNA vs GRALV Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, CDNA is priced at $22.31, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas GRALV's P/E ratio is N/A. In terms of profitability, CDNA's ROE is -0.03%, compared to GRALV's ROE of N/A. Regarding short-term risk, CDNA is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check GRALV's competition here
CDNA vs FLGT Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, FLGT has a market cap of 515.2M. Regarding current trading prices, CDNA is priced at $22.31, while FLGT trades at $18.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas FLGT's P/E ratio is -7.56. In terms of profitability, CDNA's ROE is -0.03%, compared to FLGT's ROE of -0.07%. Regarding short-term risk, CDNA is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check FLGT's competition here
CDNA vs MYGN Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, MYGN has a market cap of 415.6M. Regarding current trading prices, CDNA is priced at $22.31, while MYGN trades at $4.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas MYGN's P/E ratio is -1.02. In terms of profitability, CDNA's ROE is -0.03%, compared to MYGN's ROE of -1.09%. Regarding short-term risk, CDNA is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check MYGN's competition here
CDNA vs CO Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, CDNA is priced at $22.31, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas CO's P/E ratio is 5.06. In terms of profitability, CDNA's ROE is -0.03%, compared to CO's ROE of +0.11%. Regarding short-term risk, CDNA is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check CO's competition here
CDNA vs PRE Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, PRE has a market cap of 354.1M. Regarding current trading prices, CDNA is priced at $22.31, while PRE trades at $20.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas PRE's P/E ratio is -8.47. In terms of profitability, CDNA's ROE is -0.03%, compared to PRE's ROE of -0.36%. Regarding short-term risk, CDNA is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check PRE's competition here
CDNA vs FLDM Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, CDNA is priced at $22.31, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas FLDM's P/E ratio is -4.74. In terms of profitability, CDNA's ROE is -0.03%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, CDNA is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check FLDM's competition here
CDNA vs NEO Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, NEO has a market cap of 264.1M. Regarding current trading prices, CDNA is priced at $22.31, while NEO trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas NEO's P/E ratio is -13.17. In terms of profitability, CDNA's ROE is -0.03%, compared to NEO's ROE of -0.12%. Regarding short-term risk, CDNA is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check NEO's competition here
CDNA vs OPGN Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, OPGN has a market cap of 242.7M. Regarding current trading prices, CDNA is priced at $22.31, while OPGN trades at $23.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas OPGN's P/E ratio is 132.83. In terms of profitability, CDNA's ROE is -0.03%, compared to OPGN's ROE of +1.58%. Regarding short-term risk, CDNA is more volatile compared to OPGN. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check OPGN's competition here
CDNA vs IMDX Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, IMDX has a market cap of 161.9M. Regarding current trading prices, CDNA is priced at $22.31, while IMDX trades at $6.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas IMDX's P/E ratio is -3.99. In terms of profitability, CDNA's ROE is -0.03%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, CDNA is less volatile compared to IMDX. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check IMDX's competition here
CDNA vs BDSX Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, BDSX has a market cap of 131.1M. Regarding current trading prices, CDNA is priced at $22.31, while BDSX trades at $16.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas BDSX's P/E ratio is -4.07. In terms of profitability, CDNA's ROE is -0.03%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, CDNA is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check BDSX's competition here
CDNA vs GTH Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, CDNA is priced at $22.31, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas GTH's P/E ratio is -1.11. In terms of profitability, CDNA's ROE is -0.03%, compared to GTH's ROE of -1.01%. Regarding short-term risk, CDNA is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check GTH's competition here
CDNA vs GENE Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, CDNA is priced at $22.31, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas GENE's P/E ratio is -38.25. In terms of profitability, CDNA's ROE is -0.03%, compared to GENE's ROE of -1.85%. Regarding short-term risk, CDNA is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check GENE's competition here
CDNA vs XGN Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, XGN has a market cap of 109.7M. Regarding current trading prices, CDNA is priced at $22.31, while XGN trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas XGN's P/E ratio is -5.04. In terms of profitability, CDNA's ROE is -0.03%, compared to XGN's ROE of -1.14%. Regarding short-term risk, CDNA is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check XGN's competition here
CDNA vs ATLN Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, ATLN has a market cap of 107.1M. Regarding current trading prices, CDNA is priced at $22.31, while ATLN trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas ATLN's P/E ratio is -1.25. In terms of profitability, CDNA's ROE is -0.03%, compared to ATLN's ROE of +2.74%. Regarding short-term risk, CDNA is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check ATLN's competition here
CDNA vs STIM Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, STIM has a market cap of 96.7M. Regarding current trading prices, CDNA is priced at $22.31, while STIM trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas STIM's P/E ratio is -2.57. In terms of profitability, CDNA's ROE is -0.03%, compared to STIM's ROE of -1.65%. Regarding short-term risk, CDNA is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check STIM's competition here
CDNA vs SERA Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, SERA has a market cap of 78.3M. Regarding current trading prices, CDNA is priced at $22.31, while SERA trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas SERA's P/E ratio is -3.20. In terms of profitability, CDNA's ROE is -0.03%, compared to SERA's ROE of -0.41%. Regarding short-term risk, CDNA is more volatile compared to SERA. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check SERA's competition here
CDNA vs DRIO Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, DRIO has a market cap of 54M. Regarding current trading prices, CDNA is priced at $22.31, while DRIO trades at $7.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas DRIO's P/E ratio is -0.87. In terms of profitability, CDNA's ROE is -0.03%, compared to DRIO's ROE of +0.93%. Regarding short-term risk, CDNA is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check DRIO's competition here
CDNA vs PRPO Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, PRPO has a market cap of 43M. Regarding current trading prices, CDNA is priced at $22.31, while PRPO trades at $24.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas PRPO's P/E ratio is -53.42. In terms of profitability, CDNA's ROE is -0.03%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, CDNA is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check PRPO's competition here
CDNA vs STRR Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, STRR has a market cap of 42.7M. Regarding current trading prices, CDNA is priced at $22.31, while STRR trades at $11.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas STRR's P/E ratio is -4.62. In terms of profitability, CDNA's ROE is -0.03%, compared to STRR's ROE of -0.14%. Regarding short-term risk, CDNA is more volatile compared to STRR. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check STRR's competition here
CDNA vs STRRP Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, STRRP has a market cap of 32.9M. Regarding current trading prices, CDNA is priced at $22.31, while STRRP trades at $9.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas STRRP's P/E ratio is -4.87. In terms of profitability, CDNA's ROE is -0.03%, compared to STRRP's ROE of -0.14%. Regarding short-term risk, CDNA is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check STRRP's competition here
CDNA vs MDXH Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, MDXH has a market cap of 31M. Regarding current trading prices, CDNA is priced at $22.31, while MDXH trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas MDXH's P/E ratio is -0.93. In terms of profitability, CDNA's ROE is -0.03%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, CDNA is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check MDXH's competition here
CDNA vs QUCY Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, QUCY has a market cap of 30.8M. Regarding current trading prices, CDNA is priced at $22.31, while QUCY trades at $2.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas QUCY's P/E ratio is -0.11. In terms of profitability, CDNA's ROE is -0.03%, compared to QUCY's ROE of -2.44%. Regarding short-term risk, CDNA is less volatile compared to QUCY. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check QUCY's competition here
CDNA vs AKU Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, CDNA is priced at $22.31, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas AKU's P/E ratio is -0.13. In terms of profitability, CDNA's ROE is -0.03%, compared to AKU's ROE of -5.32%. Regarding short-term risk, CDNA is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check AKU's competition here
CDNA vs CEMI Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, CDNA is priced at $22.31, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas CEMI's P/E ratio is -0.63. In terms of profitability, CDNA's ROE is -0.03%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, CDNA is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check CEMI's competition here
CDNA vs ENZ Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, CDNA is priced at $22.31, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas ENZ's P/E ratio is -2.85. In terms of profitability, CDNA's ROE is -0.03%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, CDNA is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check ENZ's competition here
CDNA vs PMD Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, CDNA is priced at $22.31, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas PMD's P/E ratio is -5.24. In terms of profitability, CDNA's ROE is -0.03%, compared to PMD's ROE of -0.32%. Regarding short-term risk, CDNA is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check PMD's competition here
CDNA vs ME Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, CDNA is priced at $22.31, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas ME's P/E ratio is -0.03. In terms of profitability, CDNA's ROE is -0.03%, compared to ME's ROE of -7.71%. Regarding short-term risk, CDNA is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check ME's competition here
CDNA vs MYNZ Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, CDNA is priced at $22.31, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, CDNA's ROE is -0.03%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, CDNA is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check MYNZ's competition here
CDNA vs VNRX Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, VNRX has a market cap of 11.3M. Regarding current trading prices, CDNA is priced at $22.31, while VNRX trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas VNRX's P/E ratio is -0.50. In terms of profitability, CDNA's ROE is -0.03%, compared to VNRX's ROE of +0.74%. Regarding short-term risk, CDNA is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check VNRX's competition here
CDNA vs CHEK Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, CDNA is priced at $22.31, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas CHEK's P/E ratio is -0.43. In terms of profitability, CDNA's ROE is -0.03%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, CDNA is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check CHEK's competition here
CDNA vs CNTG Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, CDNA is priced at $22.31, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas CNTG's P/E ratio is -0.23. In terms of profitability, CDNA's ROE is -0.03%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, CDNA is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check CNTG's competition here
CDNA vs BNR Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, BNR has a market cap of 9.4M. Regarding current trading prices, CDNA is priced at $22.31, while BNR trades at $8.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas BNR's P/E ratio is -11.48. In terms of profitability, CDNA's ROE is -0.03%, compared to BNR's ROE of -0.10%. Regarding short-term risk, CDNA is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check BNR's competition here
CDNA vs MBAI Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, MBAI has a market cap of 9M. Regarding current trading prices, CDNA is priced at $22.31, while MBAI trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas MBAI's P/E ratio is 2.32. In terms of profitability, CDNA's ROE is -0.03%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, CDNA is less volatile compared to MBAI. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check MBAI's competition here
CDNA vs BIAF Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, BIAF has a market cap of 7.7M. Regarding current trading prices, CDNA is priced at $22.31, while BIAF trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas BIAF's P/E ratio is -0.36. In terms of profitability, CDNA's ROE is -0.03%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, CDNA is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check BIAF's competition here
CDNA vs TRIB Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, TRIB has a market cap of 7.3M. Regarding current trading prices, CDNA is priced at $22.31, while TRIB trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas TRIB's P/E ratio is -0.35. In terms of profitability, CDNA's ROE is -0.03%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, CDNA is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check TRIB's competition here
CDNA vs APDN Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, CDNA is priced at $22.31, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas APDN's P/E ratio is -0.10. In terms of profitability, CDNA's ROE is -0.03%, compared to APDN's ROE of -6.53%. Regarding short-term risk, CDNA is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check APDN's competition here
CDNA vs NVTA Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, CDNA is priced at $22.31, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas NVTA's P/E ratio is -0.00. In terms of profitability, CDNA's ROE is -0.03%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, CDNA is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check NVTA's competition here
CDNA vs LMDXW Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, CDNA is priced at $22.31, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, CDNA's ROE is -0.03%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, CDNA is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check LMDXW's competition here
CDNA vs LMDX Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, CDNA is priced at $22.31, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas LMDX's P/E ratio is -0.01. In terms of profitability, CDNA's ROE is -0.03%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, CDNA is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check LMDX's competition here
CDNA vs ADVB Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, ADVB has a market cap of 5.1M. Regarding current trading prices, CDNA is priced at $22.31, while ADVB trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas ADVB's P/E ratio is 1.17. In terms of profitability, CDNA's ROE is -0.03%, compared to ADVB's ROE of -0.65%. Regarding short-term risk, CDNA is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check ADVB's competition here
CDNA vs BGLC Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, BGLC has a market cap of 4.6M. Regarding current trading prices, CDNA is priced at $22.31, while BGLC trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas BGLC's P/E ratio is -1.53. In terms of profitability, CDNA's ROE is -0.03%, compared to BGLC's ROE of -0.37%. Regarding short-term risk, CDNA is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check BGLC's competition here
CDNA vs BNGO Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, BNGO has a market cap of 4.3M. Regarding current trading prices, CDNA is priced at $22.31, while BNGO trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas BNGO's P/E ratio is -0.29. In terms of profitability, CDNA's ROE is -0.03%, compared to BNGO's ROE of -0.71%. Regarding short-term risk, CDNA is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check BNGO's competition here
CDNA vs NOTV Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, NOTV has a market cap of 4.1M. Regarding current trading prices, CDNA is priced at $22.31, while NOTV trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas NOTV's P/E ratio is -0.05. In terms of profitability, CDNA's ROE is -0.03%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, CDNA is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check NOTV's competition here
CDNA vs NDRA Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, NDRA has a market cap of 3.6M. Regarding current trading prices, CDNA is priced at $22.31, while NDRA trades at $4.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas NDRA's P/E ratio is -0.58. In terms of profitability, CDNA's ROE is -0.03%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, CDNA is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check NDRA's competition here
CDNA vs DMTK Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, CDNA is priced at $22.31, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas DMTK's P/E ratio is -0.04. In terms of profitability, CDNA's ROE is -0.03%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, CDNA is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check DMTK's competition here
CDNA vs SQL Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, CDNA is priced at $22.31, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas SQL's P/E ratio is -0.40. In terms of profitability, CDNA's ROE is -0.03%, compared to SQL's ROE of +2.74%. Regarding short-term risk, CDNA is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check SQL's competition here
CDNA vs AWH Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, CDNA is priced at $22.31, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas AWH's P/E ratio is -0.09. In terms of profitability, CDNA's ROE is -0.03%, compared to AWH's ROE of +2.03%. Regarding short-term risk, CDNA is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check AWH's competition here
CDNA vs INBS Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, INBS has a market cap of 1.6M. Regarding current trading prices, CDNA is priced at $22.31, while INBS trades at $2.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas INBS's P/E ratio is -0.21. In terms of profitability, CDNA's ROE is -0.03%, compared to INBS's ROE of -1.74%. Regarding short-term risk, CDNA is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check INBS's competition here
CDNA vs HTGM Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, CDNA is priced at $22.31, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas HTGM's P/E ratio is -0.03. In terms of profitability, CDNA's ROE is -0.03%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, CDNA is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check HTGM's competition here
CDNA vs BIAFW Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, BIAFW has a market cap of 899.4K. Regarding current trading prices, CDNA is priced at $22.31, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas BIAFW's P/E ratio is N/A. In terms of profitability, CDNA's ROE is -0.03%, compared to BIAFW's ROE of -3.59%. Regarding short-term risk, CDNA is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check BIAFW's competition here
CDNA vs BIOC Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, CDNA is priced at $22.31, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas BIOC's P/E ratio is -0.01. In terms of profitability, CDNA's ROE is -0.03%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, CDNA is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check BIOC's competition here
CDNA vs ISPC Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, ISPC has a market cap of 416.6K. Regarding current trading prices, CDNA is priced at $22.31, while ISPC trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas ISPC's P/E ratio is -0.01. In terms of profitability, CDNA's ROE is -0.03%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, CDNA is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check ISPC's competition here
CDNA vs PRENW Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, PRENW has a market cap of 224.8K. Regarding current trading prices, CDNA is priced at $22.31, while PRENW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas PRENW's P/E ratio is N/A. In terms of profitability, CDNA's ROE is -0.03%, compared to PRENW's ROE of -0.36%. Regarding short-term risk, CDNA is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check PRENW's competition here
CDNA vs SQLLW Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, SQLLW has a market cap of 164.5K. Regarding current trading prices, CDNA is priced at $22.31, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, CDNA's ROE is -0.03%, compared to SQLLW's ROE of +2.74%. Regarding short-term risk, CDNA is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check SQLLW's competition here
CDNA vs TTOO Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, TTOO has a market cap of 56.1K. Regarding current trading prices, CDNA is priced at $22.31, while TTOO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas TTOO's P/E ratio is -0.07. In terms of profitability, CDNA's ROE is -0.03%, compared to TTOO's ROE of +1.47%. Regarding short-term risk, CDNA is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check TTOO's competition here
CDNA vs OCDX Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, CDNA is priced at $22.31, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas OCDX's P/E ratio is -42.28. In terms of profitability, CDNA's ROE is -0.03%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, CDNA is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check OCDX's competition here
CDNA vs DHR-PA Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, CDNA is priced at $22.31, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, CDNA's ROE is -0.03%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, CDNA is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check DHR-PA's competition here
CDNA vs CHEKZ Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, CDNA is priced at $22.31, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, CDNA's ROE is -0.03%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, CDNA is less volatile compared to CHEKZ. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check CHEKZ's competition here
CDNA vs NDRAW Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, CDNA is priced at $22.31, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas NDRAW's P/E ratio is N/A. In terms of profitability, CDNA's ROE is -0.03%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, CDNA is less volatile compared to NDRAW. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check NDRAW's competition here
CDNA vs MEUSW Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, CDNA is priced at $22.31, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas MEUSW's P/E ratio is N/A. In terms of profitability, CDNA's ROE is -0.03%, compared to MEUSW's ROE of -7.71%. Regarding short-term risk, CDNA is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check MEUSW's competition here
CDNA vs BNGOW Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, CDNA is priced at $22.31, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas BNGOW's P/E ratio is N/A. In terms of profitability, CDNA's ROE is -0.03%, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, CDNA is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for CDNA.Check BNGOW's competition here
CDNA vs PRXL Comparison June 2026
CDNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDNA stands at 1.2B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, CDNA is priced at $22.31, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDNA currently has a P/E ratio of -139.44, whereas PRXL's P/E ratio is N/A. In terms of profitability, CDNA's ROE is -0.03%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, CDNA is more volatile compared to PRXL. This indicates potentially higher risk in terms of short-term price fluctuations for CDNA.Check PRXL's competition here